

DAFTAR PUSTAKA

- Akinleye, Akintunde, and Zoab Rasool. 2019. "Immune Checkpoint Inhibitors of PD-L1 as Cancer Therapeutics." *Journal of Hematology & Oncology* 12(1): 92.
- American Cancer Society. 2021. "Prostate Cancer Risk Factors." <https://www.cancer.org/cancer/prostate-cancer/causes-risks-prevention/risk-factors.html>.
- Benedettini, Elisa, Paul Nguyen, and Massimo Loda. 2008. "The Pathogenesis of Prostate Cancer: From Molecular to Metabolic Alterations." *Diagnostic Histopathology* 14(5): 195–201.
- Bostwick, David G., Liang Cheng, and Isabelle Meiers. 2014. "Epithelial Neoplasms." In *Urologic Surgical Pathology*, eds. David G. Bostwick and Liang Cheng. Philadelphia: Elsevier, 410–516.
- Bostwick, David G., David Hull, Jun Ma, and Deloar Hossain. 2014. "Anatomy and Histology of the Prostate." In *Urologic Surgical Pathology*, eds. David G. Bostwick and Liang Cheng. Philadelphia: Elsevier, 352–69.
- Brahmer, Julie R. et al. 2012. "Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer." *New England Journal of Medicine* 366(26): 2455–65.
- Chen, Fang-zhi, and Xiao-kun Zhao. 2013. "Prostate Cancer: Current Treatment and Prevention Strategies." *Iranian Red Crescent Medical Journal* 15(4): 279–84.
- Chen, J, C C Jiang, L Jin, and X D Zhang. 2016. "Regulation of PD-L1: A Novel Role of pro-Survival Signalling in Cancer." *Annals of oncology : official journal of the European Society for Medical Oncology* 27(3): 409–16.
- Chen, Nan et al. 2017. "KRAS Mutation-Induced Upregulation of PD-L1 Mediates Immune Escape in Human Lung Adenocarcinoma." *Cancer immunology, immunotherapy : CII* 66(9): 1175–87.
- D'Amico, A V et al. 1998. "Biochemical Outcome after Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer." *JAMA* 280(11): 969–74.
- Dong, Peixin et al. 2018. "Control of PD-L1 Expression by MiR-140/142/340/383 and Oncogenic Activation of the OCT4–MiR-18a Pathway in Cervical Cancer." *Oncogene* 37(39): 5257–68. <http://dx.doi.org/10.1038/s41388-018-0347-4>.
- Dong, Yinan, Qian Sun, and Xinwei Zhang. 2017. "PD-1 and Its Ligands Are Important Immune Checkpoints in Cancer." *Oncotarget* 8(2): 2171–86.
- Durand-Panteix, Stéphanie et al. 2012. "B7-H1, Which Represses EBV-Immortalized B Cell Killing by Autologous T and NK Cells, Is Oppositely Regulated by c-Myc and EBV Latency III Program at Both MRNA and Secretory Lysosome Levels." *Journal of immunology (Baltimore, Md. : 1950)* 189(1): 181–90.
- El-sharkawy, Ahmed, and Ahmed Malki. 2014. "Tumor Immunology and Immunotherapy." In *Cancer Treatment Strategies*, ed. Ahmed Malki. USA: OMICS Group eBooks, 4–13.
- Epstein, J. I. and Lotan, T. L. 2018. "Male Genital System and Lower Urinary Tract." In *Robbins Basic Pathology*, eds. Abul K. Abbas, Jon C. Aster, and James A. Perkins. Philadelphia: Elsevier, 671–99.
- Epstein, Jonathan I et al. 2016. "A Contemporary Prostate Cancer Grading

- System: A Validated Alternative to the Gleason Score.” *European urology* 69(3): 428–35.
- Eroschenko, Victor P., ed. 2013. “Male Reproductive System.” In *Di Fiore’s Atlas of Histology with Functional Correlations*, Philadelphia: Lippincott Williams & Wilkins, 494–99.
- Fine, Samson W, and Victor E Reuter. 2012. “Anatomy of the Prostate Revisited: Implications for Prostate Biopsy and Zonal Origins of Prostate Cancer.” *Histopathology* 60(1): 142–52.
- Gainor, Justin F et al. 2015. “Clinical Correlation and Frequency of Programmed Death Ligand-1 (PD-L1) Expression in EGFR-Mutant and ALK-Rearranged Non-Small Cell Lung Cancer (NSCLC).” *Journal of Clinical Oncology* 33(15_suppl): 8012. https://doi.org/10.1200/jco.2015.33.15_suppl.8012.
- Gong, Ai-Yu et al. 2009. “MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN-Gamma-Induced B7-H1 Expression in Cholangiocytes.” *Journal of immunology (Baltimore, Md. : 1950)* 182(3): 1325–33. <https://pubmed.ncbi.nlm.nih.gov/19155478>.
- Guan, Jian, Khin Sandar Lim, Tarek Mekhail, and Chung-Che Chang. 2017. “Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers.” *Archives of Pathology & Laboratory Medicine* 141(6): 851–61.
- Haas, Gabriel P, and Wael A Sakr. 1997. “Epidemiology of Prostate Cancer.” *CA: A Cancer Journal for Clinicians* 47(5): 273–87.
- Haffner, Michael C et al. 2018. “Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.” *The American Journal of Pathology* 188(6): 1478–85.
- Hammerich, Kai H., Gustavo E. Ayala, and Thomas M. Wheeler. 2008. “Anatomy of the Prostate Gland and Surgical Pathology of Prostate Cancer.” In *Prostate Cancer*, eds. Hedvig Hricak and Peter Scardino. Cambridge: Cambridge University Press, 1–14.
- He, Jiabei, Ying Hu, Mingming Hu, and Baolan Li. 2015. “Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.” *Scientific Reports* 5(1): 13110. <https://doi.org/10.1038/srep13110>.
- He, Jing et al. 2018. “Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications.” *American Journal of Clinical Pathology* 149(3): 253–61.
- Hsieh, Annie L et al. 2015. “MYC and Metabolism on the Path to Cancer.” *Seminars in cell & developmental biology* 43: 11–21.
- Humphrey, P.A. et al. 2016. “Acinar Adenocarcinoma.” In *WHO Classification of Tumours of the Urinary System and Male Genital Organs*, eds. Holger Moch, Peter A. Humphrey, Thomas M. Ulbright, and Victor E. Reuter. Lyon: IARC, 138–62.
- Isaacsson Velho, Pedro, and Emmanuel S Antonarakis. 2018. “PD-1/PD-L1 Pathway Inhibitors in Advanced Prostate Cancer.” *Expert Review of Clinical Pharmacology* 11(5): 475–86.
- Ju, Xiaoli, Heng Zhang, Zidi Zhou, and Qiang Wang. 2020. “Regulation of PD-L1 Expression in Cancer and Clinical Implications in Immunotherapy.” *American journal of cancer research* 10(1): 1–11. <http://www.ncbi.nlm.nih.gov/pubmed/32064150><http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7017746>.

- Kryvenko, Oleksandr N., and Jonathan I. Epstein. 2016. "Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System." *Archives of Pathology & Laboratory Medicine* 140(10): 1140–52.
- Kumar, Ravi J, Al Baha Barqawi, and E David Crawford. 2005. "Epidemiology of Prostate Cancer." *Oncology & Hematology Review (US)* 00(00): 1.
- Kumar, Sachin, and Surender Kumar Sharawat. 2018. "Epigenetic Regulators of Programmed Death-Ligand 1 Expression in Human Cancers." *Translational research : the journal of laboratory and clinical medicine* 202: 129–45.
- Li, Heng et al. 2019. "The Immune Checkpoint Regulator PDL1 Is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy." *Journal of Cancer* 10(14): 3102–11.
- Li, Yan et al. 2019. "The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis." *Frontiers in Pharmacology* 9(JAN).
- Lim, Seung-Oe et al. 2016. "Deubiquitination and Stabilization of PD-L1 by CSN5." *Cancer cell* 30(6): 925–39.
- MacLennan, Gregory T, and Liang Cheng, eds. 2011. "Prostat." In *Atlas of Genitourinary Pathology*, London: Springer London, 215–83.
- McKenney, Jesse K. 2018. "Prostate and Seminal Vesicles." In *Rosai and Ackerman's Surgical Pathology*, eds. John R. Goldblum, Laura W. Lamps, Jesse K. McKenney, and Jeffrey L. Myers. Philadelphia: Elsevier, 1104–19.
- Meng, Xiangjiao et al. 2015. "Predictive Biomarkers in PD-1/PD-L1 Checkpoint Blockade Immunotherapy." *Cancer treatment reviews* 41(10): 868–76.
- Mezzadra, Riccardo et al. 2017. "Identification of CMTM6 and CMTM4 as PD-L1 Protein Regulators." *Nature* 549(7670): 106–10.
<https://doi.org/10.1038/nature23669>.
- Mustafa, Murtaza et al. 2016. "Prostate Cancer : Pathophysiology, Diagnosis, and Prognosis." *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)* 15(6): 4–11.
- Paner, Gladell P. 2016. "Prostate Gland and Seminal Vesicle : Introduction and Overview." In *Diagnostic Pathology Genitourinary*, eds. Mahul B. Amin and Satish K. Tickoo. Philadelphia: Elsevier, 536–53.
- Paner, Gladell P, Jatin Gandhi, Bonnie Choy, and Mahul B Amin. 2019. "Essential Updates in Grading, Morphotyping, Reporting, and Staging of Prostate Carcinoma for General Surgical Pathologists." *Archives of Pathology & Laboratory Medicine* 143(5): 550–64.
- Passardi, Alessandro, Matteo Canale, Martina Valgiusti, and Paola Ulivi. 2017. "Immune Checkpoints as a Target for Colorectal Cancer Treatment." *International Journal of Molecular Sciences* 18(6): 1324.
- Pedomon Nasional Pelayanan Kedokteran Kanker Prostat*. 2017. Jakarta: Komite Penanggulangan Kanker Nasional Kementrian Kesehatan RI.
- Rawla, Prashanth. 2019. "Epidemiology of Prostate Cancer." *World Journal of Oncology* 10(2): 63–89.
- Reeves, Fairleigh, Wouter Everaerts, Declan G Murphy, and Anthony Costello. 2016. "The Surgical Anatomy of the Prostate." In *Prostate Cancer*, eds. Jack H. Mydlo and Cyril J. Godec. Philadelphia: Elsevier, 253–63.
- Selman, Steven H. 2011. "The McNeal Prostate: A Review." *Urology* 78(6): 1224–28.

- Shah, Rajal B., and Ming Zhou. 2012. Prostate Biopsy Interpretation: An Illustrated Guide *Prostate Biopsy Interpretation: An Illustrated Guide*. Berlin, Heidelberg: Springer Berlin Heidelberg.
- Shah, Rajal B, and Ming Zhou. 2016. "Recent Advances in Prostate Cancer Pathology: Gleason Grading and Beyond." *Pathology International* 66(5): 260–72.
- Sharma, Meenal, Zhiming Yang, Hiroshi Miyamoto, and Giuseppe Lucarelli. 2019. "Immunohistochemistry of Immune Checkpoint Markers PD-1 and PD-L1 in Prostate Cancer." *Medicine (United States)* 98(38): 1–6.
- Sharpe, Arlene H, E John Wherry, Rafi Ahmed, and Gordon J Freeman. 2007. "The Function of Programmed Cell Death 1 and Its Ligands in Regulating Autoimmunity and Infection." *Nature Immunology* 8(3): 239–45. <https://doi.org/10.1038/ni1443>.
- Shehade, Hussein, Guillaume Oldenhove, and Muriel Moser. 2014. "Hypoxia in the Intestine or Solid Tumors: A Beneficial or Deleterious Alarm Signal?" *European journal of immunology* 44(9): 2550–57.
- Shen, Michael M, and Cory Abate-Shen. 2010. "Molecular Genetics of Prostate Cancer: New Prospects for Old Challenges." *Genes & Development* 24(18): 1967–2000.
- "Situasi Penyakit Kanker." 2015. *InfoDATIN*: 1–6.
- Velcheti, Vamsidhar, Satish Karnik, Stephen F Bardot, and Om Prakash. 2008. "Pathogenesis of Prostate Cancer: Lessons from Basic Research." *The Ochsner journal* 8(4): 213–18.
- Wang, A et al. 2015. "The Prognostic Value of PD-L1 Expression for Non-Small Cell Lung Cancer Patients: A Meta-Analysis." *European Journal of Surgical Oncology (EJSO)* 41(4): 450–56. <https://www.sciencedirect.com/science/article/pii/S0748798315000530>.
- Wang, Weipeng et al. 2013. "A MiR-570 Binding Site Polymorphism in the B7-H1 Gene Is Associated with the Risk of Gastric Adenocarcinoma." *Human genetics* 132(6): 641–48.
- Wang, Xin, Feifei Teng, Li Kong, and Jinming Yu. 2016. "PD-L1 Expression in Human Cancers and Its Association with Clinical Outcomes." *Oncotargets and Therapy* 9(Oncotarget and Therapy): 5023–39.
- Wang, Xun et al. 2017. "Inflammatory Cytokines IL-17 and TNF- α up-Regulate PD-L1 Expression in Human Prostate and Colon Cancer Cells." *Immunology Letter* April(184): 7–14.
- Xian, Peng et al. 2019. "PD-L1 Instead of PD-1 Status Is Associated with the Clinical Features in Human Primary Prostate Tumors." *American journal of clinical and experimental urology* 7(3): 159–69.
- Xu, Li Jun et al. 2018. "Inhibition of IL-6-JAK/Stat3 Signaling in Castration-Resistant Prostate Cancer Cells Enhances the NK Cell-Mediated Cytotoxicity via Alteration of PD-L1/NKG2D Ligand Levels." *Molecular Oncology* 12(3): 269–86.
- Zak, Krzysztof M. et al. 2017. "Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2." *Structure* 25(8): 1163–74.
- Zelevsky, Michael J, Michael J Morris, and James A Eastham. 2018. "Cancer of the Prostate." In *DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology*, eds. Vincent T. DeVita, Theodore S. Lawrence, and Steven A. Rosenberg. Philadelphia: Wolters Kluwer, 1942–77.
- Zhang, Jinfang et al. 2018. "Cyclin D–CDK4 Kinase Destabilizes PD-L1 via Cullin

3–SPOP to Control Cancer Immune Surveillance.” *Nature* 553(7686): 91–95. <https://doi.org/10.1038/nature25015>.

Zou, Weiping. 2005. “Immunosuppressive Networks in the Tumour Environment and Their Therapeutic Relevance.” *Nature Reviews Cancer* 5(4): 263–74.

LAMPIRAN

DATA SAMPEL

no	sediaan	umur	grading	intensity	persentase	SQ-Score
1	33741	62	1	0	0	0
2	P18.4245	60	1	0	0	0
3	P18.1478	72	1	2	50	100
4	P18.4691	70	1	0	0	0
5	39981	58	1	1	20	20
6	38786	73	1	2	30	60
7	P19.3505	56	1	3	50	150
8	34681	49	1	1	20	20
9	41056	79	1	3	70	210
10	HUH.17.7737	66	1	1	40	40
11	P18.3089	66	1	1	30	30
12	P18.4182	70	1	1	20	20
13	37575	77	1	2	30	60
14	36704	78	1	0	0	0
15	HUH.17.0961	55	1	0	0	0
16	P18.4424	83	2	1	10	10
17	P18.3414	68	2	3	40	120
18	HUH.20106	60	2	2	40	80
19	HUH.19.190	63	2	2	30	60
20	HUH.19.1292	62	2	1	30	30
21	P20.0695	69	2	2	30	60
22	29238	63	2	1	20	20
23	P18.3566	69	2	2	30	60
24	P19.0837	64	2	2	50	100
25	35828	89	2	2	40	80
26	P18.0940	69	2	2	50	100
27	P19.0523	74	2	1	40	40
28	34676	59	2	1	20	20
29	P19.2453	74	3	3	50	150
30	35108	87	3	1	10	10
31	33502	79	3	1	20	20
32	38961	52	3	1	30	30
33	P19.1193	71	3	2	50	100
34	P18.2502	44	3	1	10	10
35	P19.1190	79	3	1	20	20

36	P18.2380	77	3	1	20	20
37	40935	62	3	3	50	150
38	HUH. 20210	52	3	2	40	80
39	37065	72	3	2	50	100
40	34384	67	3	1	20	20
41	43405	99	3	1	30	30
42	37792	75	3	1	20	20
43	P18.3768	67	4	1	20	20
44	P19.3728	69	4	2	50	100
45	38928	49	4	3	50	150
46	40451	73	4	3	70	210
47	42193	67	4	3	70	210
48	37543	71	4	2	50	100
49	P20.1571	82	4	3	90	270
50	P19.3833	66	4	1	10	10
51	P19.3301	56	4	1	30	30
52	P19.2406	74	4	2	60	120
53	P19.2228	60	4	2	50	100
54	P19.4309	53	4	3	80	240
55	P18.4630	70	4	3	70	210
56	P19.1506	69	4	3	80	240
57	P19.3408	81	5	3	90	270
58	P19.3797	74	5	3	80	240
59	P19.0368	73	5	1	80	80
60	P20.1109	79	5	3	100	300
61	P19.4133	91	5	3	100	300
62	P19.4054	81	5	2	70	140
63	P19.0214	55	5	2	80	160
64	P20.009	49	5	3	80	240
65	P20.1223	70	5	2	60	120
66	P20.0289	77	5	3	80	240
67	P20.1099	75	5	3	70	210
68	4023	74	5	3	90	270
69	P19.4472	71	5	3	80	240
70	3670	59	5	3	80	240
71	P19.4387	48	5	1	50	50

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Umur	71	100.0%	0	.0%	71	100.0%
Persentase Area Terwarnai	71	100.0%	0	.0%	71	100.0%
H-Score PD-L1	71	100.0%	0	.0%	71	100.0%

Descriptives

		Statistic	Std. Error
Umur	Mean	68.39	1.297
	95% Confidence Interval for Mean		
	Lower Bound	65.81	
	Upper Bound	70.98	
	5% Trimmed Mean	68.25	
	Median	69.00	
	Variance	119.499	
	Std. Deviation	10.932	
	Minimum	44	
	Maximum	99	
	Range	55	
	Interquartile Range	15	
	Skewness	.031	.285
Kurtosis	.102	.563	
Persentase Area Terwarnai	Mean	45.77	3.107
	95% Confidence Interval for Mean		
	Lower Bound	39.58	
	Upper Bound	51.97	
	5% Trimmed Mean	45.70	
	Median	50.00	
	Variance	685.206	
	Std. Deviation	26.176	
	Minimum	0	
	Maximum	100	
	Range	100	
	Interquartile Range	44	

	Skewness		.103	.285
	Kurtosis		-.928	.563
H-Score PD-L1	Mean		105.77	10.157
	95% Confidence Interval for Mean	Lower Bound	85.52	
		Upper Bound	126.03	
	5% Trimmed Mean		102.32	
	Median		100.00	
	Variance		7325.206	
	Std. Deviation		85.587	
	Minimum		0	
	Maximum		300	
	Range		300	
	Interquartile Range		150	
	Skewness		.595	.285
	Kurtosis		-.908	.563

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Umur	.085	71	.200 [*]	.987	71	.687
Persentase Area Terwarnai	.121	71	.012	.955	71	.013
H-Score PD-L1	.154	71	.000	.904	71	.000

a. Lilliefors Significance Correction

*. This is a lower bound of the true significance.

Statistics

		Umur Kategorik	Grade Grup WHO	Intensitas	Ekspresi PD-L1	Ekspresi H-Score
N	Valid	71	71	71	71	71
	Missing	0	0	0	0	0

Frequency Table

Umur Kategorik

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid <69 tahun	31	43.7	43.7	43.7
>=69 tahun	40	56.3	56.3	100.0
Total	71	100.0	100.0	

Grade Grup WHO

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Grup I	15	21.1	21.1	21.1
Grup II	13	18.3	18.3	39.4
Grup III	14	19.7	19.7	59.2
Grup IV	14	19.7	19.7	78.9
Grup V	15	21.1	21.1	100.0
Total	71	100.0	100.0	

Intensitas

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid negatif	5	7.0	7.0	7.0
terwarnai lemah	20	28.2	28.2	35.2
terwarnai sedang	23	32.4	32.4	67.6
terwarnai kuat	23	32.4	32.4	100.0
Total	71	100.0	100.0	


Ekspresi PD-L1



		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Negatif	5	7.0	7.0	7.0
	Positif	66	93.0	93.0	100.0
	Total	71	100.0	100.0	



Ekspresi H-Score

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Low Expression	35	49.3	49.3	49.3
	High Expression	36	50.7	50.7	100.0
	Total	71	100.0	100.0	

Bar Chart







Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Umur Kategorik * Grade Grup WHO	71	100.0%	0	.0%	71	100.0%

Umur Kategorik * Grade Grup WHO Crosstabulation

			Grade Grup WHO			
			Grup I	Grup II	Grup III	Grup IV
Umur Kategorik	<69 tahun	Count	8	7	5	7
		% of Total	11.3%	9.9%	7.0%	9.9%
	≥69 tahun	Count	7	6	9	7
		% of Total	9.9%	8.5%	12.7%	9.9%
Total	Count	15	13	14	14	
	% of Total	21.1%	18.3%	19.7%	19.7%	


Umur Kategorik * Grade Grup WHO Crosstabulation

			Grade Grup WHO	
			Grup V	Total
Umur Kategorik	<69 tahun	Count	4	31
		% of Total	5.6%	43.7%
	>=69 tahun	Count	11	40
		% of Total	15.5%	56.3%
Total	Count		15	71
	% of Total		21.1%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	3.468 ^a	4	.483
Likelihood Ratio	3.556	4	.469
Linear-by-Linear Association	1.941	1	.164
N of Valid Cases	71		

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5,68.



Crosstabs

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Umur Kategorik * Ekspresi PD-L1	71	100.0%	0	.0%	71	100.0%

Umur Kategorik * Ekspresi PD-L1 Crosstabulation

		Ekspresi PD-L1		Total
		Negatif	Positif	
Umur Kategorik <69 tahun	Count	3	28	31
	% of Total	4.2%	39.4%	43.7%
>=69 tahun	Count	2	38	40


	% of Total	2.8%	53.5%	56.3%
Total	Count	5	66	71
	% of Total	7.0%	93.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.584 ^a	1	.445		
Continuity Correction ^b	.088	1	.767		
Likelihood Ratio	.578	1	.447		
Fisher's Exact Test				.647	.379
Linear-by-Linear Association	.575	1	.448		
N of Valid Cases	71				

a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is 2,18.

b. Computed only for a 2x2 table



Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Grade Grup WHO * Ekspresi PD-L1	71	100.0%	0	.0%	71	100.0%


Grade Grup WHO * Ekspresi PD-L1 Crosstabulation

			Ekspresi PD-L1		Total
			Negatif	Positif	
Grade Grup WHO	Grup I	Count	5	10	15
		% of Total	7.0%	14.1%	21.1%
	Grup II	Count	0	13	13
		% of Total	.0%	18.3%	18.3%
	Grup III	Count	0	14	14
		% of Total	.0%	19.7%	19.7%
	Grup IV	Count	0	14	14
		% of Total	.0%	19.7%	19.7%
	Grup V	Count	0	15	15
		% of Total	.0%	21.1%	21.1%
Total	Count	5	66	71	
	% of Total	7.0%	93.0%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	20.081 ^a	4	.000
Likelihood Ratio	17.076	4	.002
Linear-by-Linear Association	10.391	1	.001
N of Valid Cases	71		

a. 5 cells (50,0%) have expected count less than 5. The minimum expected count is ,92.



Kruskal-Wallis Test

Ranks

Grade Grup WHO		N	Mean Rank
H-Score PD-L1	Grup I	15	16.07
	Grup II	13	27.00
	Grup III	14	34.46
	Grup IV	14	46.04
	Grup V	15	55.80
	Total	71	

Test Statistics^{a,b}

H-Score PD-L1	
Chi-square	33.877
df	4
Asymp. Sig.	.000

a. Kruskal Wallis Test

b. Grouping Variable: Grade

Grup WHO

Case Processing Summary

Grade Grup WHO		Cases			
		Valid		Missing	
		N	Percent	N	Percent
H-Score PD-L1	Grup I	15	100.0%	0	.0%
	Grup II	13	100.0%	0	.0%
	– Grup III	14	100.0%	0	.0%
	Grup IV	14	100.0%	0	.0%
	Grup V	15	100.0%	0	.0%

Case Processing Summary

Grade Grup WHO		Cases	
		Total	
		N	Percent
H-Score PD-L1	Grup I	15	100.0%
	Grup II	13	100.0%
	– Grup III	14	100.0%
	Grup IV	14	100.0%
	Grup V	15	100.0%

Descriptives

Grade Grup WHO			Statistic	Std. Error	
H-Score PD-L1	Grup I	Mean	32.00	9.769	
		95% Confidence Interval for			
		Mean	Lower Bound	11.05	
			Upper Bound	52.95	
		5% Trimmed Mean		28.89	
		Median		20.00	
		Variance		1431.429	
		Std. Deviation		37.834	
		Minimum		0	
		Maximum		120	
		Range		120	
		Interquartile Range		60	
		Skewness		1.310	.580
		Kurtosis		.957	1.121
	Grup II	Mean	60.00	9.674	
		95% Confidence Interval for			
		Mean	Lower Bound	38.92	
			Upper Bound	81.08	
		5% Trimmed Mean		59.44	
		Median		60.00	
		Variance		1216.667	
		Std. Deviation		34.881	
		Minimum		10	
		Maximum		120	
		Range		110	
		Interquartile Range		65	
		Skewness		.167	.616
		Kurtosis		-1.064	1.191
	Grup III	Mean	93.14	19.414	
		95% Confidence Interval for			
		Mean	Lower Bound	51.20	
			Upper Bound	135.08	
		5% Trimmed Mean		89.05	
		Median		80.00	
		Variance		5276.747	
		Std. Deviation		72.641	
		Minimum		20	
		Maximum		240	
		Range		220	

	Interquartile Range		120	
	Skewness		.813	.597
	Kurtosis		-.397	1.154
Grup IV	Mean		146.86	22.242
	95% Confidence Interval for Mean	Lower Bound	98.81	
		Upper Bound	194.91	
	5% Trimmed Mean		147.06	
	Median		135.00	
	Variance		6925.978	
	Std. Deviation		83.222	
	Minimum		20	
	Maximum		270	
	Range		250	
	Interquartile Range		128	
	Skewness		-.086	.597
	Kurtosis		-1.360	1.154
Grup V	Mean		192.67	18.451
	95% Confidence Interval for Mean	Lower Bound	153.09	
		Upper Bound	232.24	
	5% Trimmed Mean		194.63	
	Median		210.00	
	Variance		5106.667	
	Std. Deviation		71.461	
	Minimum		50	
	Maximum		300	
	Range		250	
	Interquartile Range		100	
	Skewness		-.603	.580
	Kurtosis		-.373	1.121

Tests of Normality

Grade Grup WHO		Kolmogorov-Smirnov ^a			Shapiro-Wilk
		Statistic	df	Sig.	Statistic
H-Score PD-L1	Grup I	.224	15	.041	.821
	Grup II	.115	13	.200*	.950
	Grup III	.196	14	.149	.880
	Grup IV	.205	14	.116	.926
	Grup V	.213	15	.066	.938

a. Lilliefors Significance Correction



*. This is a lower bound of the true significance.



Tests of Normality


Grade Grup WHO		Shapiro-Wilk	
		df	Sig.
H-Score PD-L1	Grup I	15	.007
	Grup II	13	.597
	Grup III	14	.058
	Grup IV	14	.267
	Grup V	15	.363

H-Score PD-L1


Histograms







Normal Q-Q Plots



Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Grade Grup WHO * Ekspresi H-Score	71	100.0%	0	.0%	71	100.0%


Grade Grup WHO * Ekspresi H-Score Crosstabulation

			Ekspresi H-Score		Total
			Low Expression	High Expression	
Grade Grup WHO	Grup I	Count	13	2	15
		% of Total	18.3%	2.8%	21.1%
	Grup II	Count	10	3	13
		% of Total	14.1%	4.2%	18.3%
	Grup III	Count	7	7	14
		% of Total	9.9%	9.9%	19.7%
	Grup IV	Count	3	11	14
		% of Total	4.2%	15.5%	19.7%
	Grup V	Count	2	13	15
		% of Total	2.8%	18.3%	21.1%
Total	Count	35	36	71	
	% of Total	49.3%	50.7%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	24.465 ^a	4	.000
Likelihood Ratio	26.851	4	.000
Linear-by-Linear Association	23.342	1	.000
N of Valid Cases	71		

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 6,41.








REKOMENDASI PERSETUJUAN ETIK

Nomor : 129/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 26 Februari 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21020105	No Sponsor Protokol	
Peneliti Utama	dr. Nurwahida Achmad	Sponsor	
Judul Peneliti	HUBUNGAN EKSPRESI PROGRAMMED DEATH-LIGAND (PD-L1) DENGAN GRADING ADENOKARSINOMA PROSTAT		
No Versi Protokol	1	Tanggal Versi	19 Februari 2021
No Versi PSP		Tanggal Versi	
Tempat Penelitian	Laboratorium Patologi Anatomi Fakultas Kedokteran Universitas Hasanuddin Makassar		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 26 Februari 2021 sampai 26 Februari 2022	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan